Skeletal complications and the use of bisphosphonates in metastatic prostate cancer.
Metastatic prostate cancer represents an incurable progression of the disease that accounts for the vast majority of disease related mortality and is associated with significant skeletal morbidity with events including bone pain, fractures and spinal cord compression. This article provides an overview of the bone disease in this patient group, with a specific focus on the role of bisphosphonate use, in addressing quality of life issues. Key clinical trial data relating to bisphosphonates is presented and discussed, culminating in key management guidelines.
Drudge-Coates
Lawrence
L
Department of Urology, King's College Hospital, Denmark Hill, London, SE5 9RS, UK. L.Drudge-Coates@kingsch.nhs.uk
D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D004164:Diphosphonates / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007568:Jaw / Q000473:pathology*; D008297:Male; D010020:Osteonecrosis / Q000139:chemically induced; D011471:Prostatic Neoplasms / Q000473:pathology*; D016896:Treatment Outcome
D004164:Diphosphonates